Intervention
Larotrectinib Sulfate
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)NCT03213704 · 2017-08-23
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGCommon conditions
Advanced Malignant Solid Neoplasm3Recurrent Glioma3Recurrent Malignant Solid Neoplasm3Refractory Malignant Solid Neoplasm3Recurrent Ependymoma2Recurrent Hepatoblastoma2Recurrent Langerhans Cell Histiocytosis2Recurrent Malignant Germ Cell Tumor2Recurrent Medulloblastoma2Recurrent Neuroblastoma2Recurrent Non-Hodgkin Lymphoma2Recurrent Osteosarcoma2Recurrent Rhabdoid Tumor2Recurrent Soft Tissue Sarcoma2Refractory Glioma2Refractory Hepatoblastoma2Refractory Langerhans Cell Histiocytosis2Refractory Malignant Germ Cell Tumor2Refractory Medulloblastoma2Refractory Neuroblastoma2Refractory Non-Hodgkin Lymphoma2Refractory Osteosarcoma2Refractory Primary Central Nervous System Neoplasm2Refractory Rhabdoid Tumor2Refractory Rhabdomyosarcoma2
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
Phase mix
PHASE23
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.